Search our Database of Scientific Publications and Authors

I’m looking for a

    8147 results match your criteria Psoriatic Arthritis

    1 OF 163

    The cost-effectiveness of tight control of inflammation in early psoriatic arthritis: Economic analysis of the TICOPA trial.
    Arthritis Care Res (Hoboken) 2017 May 23. Epub 2017 May 23.
    Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapel Town Road, Leeds, United Kingdom.
    Objective: Treat-to-target approaches have proved to be effective in rheumatoid arthritis, but have not been studied in psoriatic arthritis (PsA). This study was undertaken to examine the cost effectiveness of tight control (TC) of inflammation in early psoriatic arthritis compared to standard care (SC).

    Methods: Cost effectiveness analyses were undertaken alongside a UK-based, open-label, multicentre, randomised controlled trial. Read More

    Palmoplantar pustulosis - a cross-sectional analysis in Germany.
    Dermatol Online J 2017 Apr 15;23(4). Epub 2017 Apr 15.
    Department of Dermatology and Allergology, University Bonn, Germany.
    Background: Palmoplantar pustulosis (PPP) is a recalcitrant chronic inflammatory skin disease. Data relevant for the medical care of patients with PPP are scarce. Thus, the aim of this work was to investigate the disease burden, clinical characteristics, and comorbidity of PPP patients in Germany. Read More

    The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.
    Rheumatology (Oxford) 2017 May 24. Epub 2017 May 24.
    Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
    In this review we discuss the divergent role of two closely related cytokines, IL-12 and IL-23, in shaping immune responses. In light of current therapeutic developments using biologic agents to block these two pathways, a better understanding of the immunological function of these cytokines is pivotal. Read More

    Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.
    Rheumatology (Oxford) 2017 May 24. Epub 2017 May 24.
    Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam.
    Objective.: To assess how many PsA patients with an acceptable disease state according to the treating rheumatologist have quiescent disease defined as minimal disease activity (MDA).

    Methods. Read More

    Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation.
    Reumatologia 2017 28;55(2):59-64. Epub 2017 Apr 28.
    Department of Rheumatology, Jagiellonian University Medical College, Krakow, Poland.
    Objectives: Report on one-year results from the Polish Spondyloarthritis Initiative registry (PolSPI), containing the cross-sectional analysis of clinical and imaging data as well as database methodology.

    Material And Methods: The PolSPI registry includes patients with axial (axSpA) and peripheral (perSpA) spondyloarthritis according to ASAS classification criteria, and/or patients with ankylosing spondylitis according to modified New York criteria, psoriatic arthritis according to CASPAR criteria, arthropathy in inflammatory bowel disease, reactive arthritis, juvenile spondyloarthritis or undifferentiated spondyloarthritis. Epidemiologic data and history of signs, symptoms and treatment of spondyloarthritis are collected and assessment of disease activity is performed. Read More

    Two-part models with stochastic processes for modelling longitudinal semicontinuous data: Computationally efficient inference and modelling the overall marginal mean.
    Stat Methods Med Res 2017 Jan 1:962280217710573. Epub 2017 Jan 1.
    MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
    Several researchers have described two-part models with patient-specific stochastic processes for analysing longitudinal semicontinuous data. In theory, such models can offer greater flexibility than the standard two-part model with patient-specific random effects. However, in practice, the high dimensional integrations involved in the marginal likelihood (i. Read More

    Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis.
    Reumatismo 2017 May 22;69(1):1-8. Epub 2017 May 22.
    Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso.
    Spondyloarthritis (SpAs) are a group of chronic inflammatory diseases that affect joints and enthesis with a possible involvement of other districts such as skin, eye and bowel. In SpAs, the inflammatory process could lead to both erosive damage (as in peripheral joint involvement of psoriatic arthritis), or bone formation (as in ankylosing spondylitis) with a reduction in function and quality of life. Recently, Mesenchimal stem cells (MSCs) transplant was used in different diseases, including autoimmune and inflammatory diseases, with the aim of repairing tissue damage, exploiting their regenerative capacity. Read More

    Management of psoriatic arthritis (PsA) among cutaneous psoriasis: from pathogenesis to therapy.
    G Ital Dermatol Venereol 2017 May 23. Epub 2017 May 23.
    Department of Dermatology, Edouard Herriot Hospital, Claude Bernard Lyon I University, Lyon, France -
    Psoriatic arthritis (PsA) is an inflammatory rheumatism belonging to spondylarthritis family and which occurs in about 30% of patients with psoriasis. The pathogenesis entails a genetic predisposition, environmental and immunologic factors. Most of the time, cutaneous lesions precede apparition of articular manifestations and dermatologists who treat psoriatic patients have to regularly screen for early PsA, especially in patients with risk factors (notably nail psoriasis). Read More

    Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability.
    Health Qual Life Outcomes 2017 May 22;15(1):110. Epub 2017 May 22.
    The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, 2000, Frederiksberg, Denmark.
    Background: Pain is inherent in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA) and traditionally considered to be of nociceptive origin. Emerging data suggest a potential role of augmented central pain mechanisms in subsets of patients, thus, valid instruments that can identify underlying pain mechanisms are needed. The painDETECT questionnaire (PDQ) was originally designed to differentiate between pain phenotypes. Read More

    Golimumab: A Review in Inflammatory Arthritis.
    BioDrugs 2017 Jun;31(3):263-274
    Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
    Golimumab (Simponi(®)), a fully human monoclonal antibody against tumour necrosis factor-alpha (TNFα), is given once monthly by subcutaneous injection. In the EU, golimumab is approved as monotherapy and/or in combination with methotrexate for the treatment of inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis [comprising ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] in adults, and polyarticular juvenile idiopathic arthritis (pJIA) in children. These approvals were based on the observations that golimumab was generally well tolerated and conferred some or all of the following benefits in pivotal studies in these settings: reduced signs and symptoms of arthritis; improved physical functioning and health-related quality of life; and slowed radiographic progression. Read More

    Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis.
    Eur J Health Econ 2017 May 19. Epub 2017 May 19.
    Health Technology Assessment Skåne, Skåne University Hospital, Lund, Sweden.
    We used a southern Swedish cohort of psoriasis (PSO) and psoriatic arthritis (PsA) patients and population-based referents (N = 57,800) to investigate the influence of socioeconomic and demographic factors on the probability of healthcare use and on healthcare costs when controlling for need as measured by PSO/PsA and common additional morbidities such as diabetes, depression and myocardial infarction. People with PSO/PsA were identified by ICD-10 codes in the Skåne Healthcare Register 1998-2007. Resource use and costs for years 2008-2011 were retrieved from the Skåne Healthcare Register and the Swedish Prescribed Drug Register, and socioeconomic data were retrieved from Statistics Sweden. Read More

    Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey.
    Dermatol Ther (Heidelb) 2017 May 19. Epub 2017 May 19.
    Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
    Introduction: Psoriasis patients demonstrate high interest in the role of diet on their skin condition. However, data are lacking to describe dietary interventions among psoriasis patients and associated outcomes. This study aims to identify common dietary habits, interventions and perceptions among patients with psoriasis, and to examine patient-reported skin outcomes in response to these interventions. Read More

    Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.
    Arthritis Res Ther 2017 May 18;19(1):102. Epub 2017 May 18.
    Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Box 480, 405 30, Gothenburg, Sweden.
    Background: To investigate the risk of first-time acute coronary syndrome (ACS), stroke and venous thromboembolism (VTE) in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated spondyloarthritis (uSpA), compared to each other and to the general population (GP).

    Methods: This is a prospective nationwide cohort study. Cohorts with AS (n = 6448), PsA (n = 16,063) and uSpA (n = 5190) patients and a GP (n = 266,435) cohort, were identified 2001-2009 in the Swedish National Patient and Population registers. Read More

    Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.
    Rheumatology (Oxford) 2017 May 18. Epub 2017 May 18.
    Rheumatology Clinic, Department of Medical and Biological Sciences, University Hospital Santa Maria della Misericordia, Udine.
    Objective.: To systematically review the role of musculoskeletal US in patients suffering from PsA or psoriasis (Pso) in terms of prevalence, diagnosis, prognosis, monitoring and treatment.

    Methods. Read More

    Pediatric Psoriasis Comorbidity Screening Guidelines.
    JAMA Dermatol 2017 May 17. Epub 2017 May 17.
    Departments of Dermatology and Pediatrics, Rady Children's Hospital San Diego and University of California, San Diego School of Medicine, San Diego.
    Importance: Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health.

    Objective: To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. Read More

    British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.
    Br J Dermatol 2017 May 17. Epub 2017 May 17.
    British Association of Dermatologists, London, W1T 5HQ, U.K.
    The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. Biologic therapies have now been in use for over 10 years, and with accrued patient-years exposure and clinical experience, many areas that were covered in previous versions of the guideline are now part of the Summary of Product Characteristics (SPC) and/or routine care so that specific recommendations are redundant (see Toolkit A: Summary of licensed indications and posology for biologic therapy, in Supporting information 2). Therefore, in this update we focus on areas where there has been a major change in the evidence base or clinical practice, where practice is very varied and/or where clear consensus or guidelines are lacking (see section 3. Read More

    Juvenile idiopathic arthritis in multiplex families: longitudinal follow-up.
    Int J Rheum Dis 2017 May 16. Epub 2017 May 16.
    Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
    Objective: To describe the physical, social, educational and employment status and clinical outcomes of patients with juvenile idiopathic arthritis (JIA) from multiplex families.

    Methods: All familial JIA patients were treated and had regular follow-up between 1990 and 2015 at King Faisal Specialist Hospital and Research Center (KFSH-RC), Riyadh, were included. Demographic data, disease duration, active arthritis and articular and extra-articular damage at last follow-up visit were reviewed. Read More

    HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.
    Clin Exp Dermatol 2017 May 17. Epub 2017 May 17.
    University of Dundee, College of Medicine, Dentistry, and Nursing, Dundee, UK.
    It is well documented that patients with human leucocyte antigen (HLA)-Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA-Cw6 allele with the first-line systemic treatment commonly used in psoriasis, methotrexate. Read More

    The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study.
    Arthritis Res Ther 2017 May 16;19(1):96. Epub 2017 May 16.
    Department of Rheumatology, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
    Background: In this study, we sought to compare the performance of spondyloarthritis (SpA) classification criteria sets in an international SpA cohort with patients included from five continents around the world.

    Methods: Data from the (ASAS) COMOrbidities in SPondyloArthritis (ASAS-COMOSPA) study were used. ASAS-COMOSPA is a multinational, cross-sectional study with consecutive patients diagnosed with SpA by rheumatologists worldwide. Read More

    Features of some clinical examination parameters in patients with psoriatic arthritis.
    Wiad Lek 2017 ;70(2):205-207
    Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
    Introduction: The relationship of cause-and-effect mechanisms of exacerbation and progressing with defining of the role of stress reaction in the psoriatic arthritis (PA) development has been examined in the article by analyzing the characteristics of medical history, current dynamics as well as clinical, instrumental and laboratory examinations. The objective was to study the role of basic indices of laboratory examinations of patients used clarify their role in the pathogenesis of PA.

    Materials And Methods: The concentration of trigger cytokines - IL-1β, IL-8, IL-17, IL-22, stress hormones - ACTH and cortisol, state of cell-antibody mediated immunity (CD3+, CD4+, CD8+, CD16+, CD22+, IRI, IgМ, IgG levels) in the serum of patients were defined. Read More

    No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
    Br J Dermatol 2017 May 16. Epub 2017 May 16.
    Department of Dermatology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario la Princesa, Madrid, Spain.
    Ustekinumab is a human monoclonal antibody directed against the p40 subunit of both interleukin (IL)-12 and IL-23(1) . It has shown to be very effective in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with a good safety profile(2,) .In the last ten years, the appearance of antinuclear antibodies (ANA) and the induction of autoimmune diseases during treatment with tumour necrosis factor-alpha (TNFα) inhibitors has been described (3-4) . Read More

    Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis.
    Postepy Dermatol Alergol 2017 Apr 13;34(2):126-130. Epub 2017 Apr 13.
    Department of Dermatology, School of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey.
    Introduction: Mean platelet volume (MPV) is an important marker that shows the activation and function of the platelets, which is effective in the inflammatory diseases.

    Aim: To show the relationship between MPV and the development of psoriatic arthritis (PA) in patients with psoriasis vulgaris (PV) and the correlation between MPV and psoriasis severity score (PASI).

    Material And Methods: Our study included 116 patients with psoriatic arthritis (68 female, 48 male) and 41 patients in the psoriasis group (19 female, 22 male) and 90 subjects in the control group (55 female, 35 male). Read More

    Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis.
    Clin Cosmet Investig Dermatol 2017 8;10:155-163. Epub 2017 May 8.
    Sector of Dermatology, School of Medical Sciences and University Hospital, State University of Rio de Janeiro.
    Background: Psoriatic arthritis is associated with psychosocial morbidity and decrease in quality of life. Psychiatric comorbidity also plays an important role in the impairment of quality of life and onset of fatigue.

    Objectives: This study aimed to assess the prevalence of fatigue in psoriatic arthritis patients and to correlate it to quality of life indexes, functional capacity, anxiety, depression and disease activity. Read More

    Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFα drugs early in disease course.
    Pediatr Rheumatol Online J 2017 May 15;15(1):38. Epub 2017 May 15.
    Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana, Ljubljana, Slovenia.
    Backgrounds: The purpose of the study was to evaluate the clinical and magnetic resonance imaging (MRI) outcome of cervical spine arthritis in children with juvenile idiopathic arthritis (JIA), who received anti-TNFα early in the course of cervical spine arthritis.

    Methods: Medical charts and imaging of JIA patients with cervical spine involvement were reviewed in this retrospective study. Data, including age at disease onset, JIA type, disease activity, treatment and clinical outcome were collected. Read More

    Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from Central and Eastern Europe.
    J Dermatolog Treat 2017 May 16:1-18. Epub 2017 May 16.
    k inVentiv Health , Princeton , NJ , USA.
    Background: Data are limited on the effectiveness of anti-TNF and other biologics on psoriatric arthritis (PsA) in Central and Eastern Europe (CEE). The objective of this analysis was to evaluate the efficacy of etanercept (ETN) in PsA patients from CEE.

    Methods: In PRESTA, patients were randomised to receive ETN 50 mg BIW or 50 mg QW for 12 weeks (double-blind phase), and ETN 50 mg QW for 12 additional weeks (open-label). Read More

    A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.
    Nutrients 2017 May 15;9(5). Epub 2017 May 15.
    Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark.
    Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Read More

    Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Lancet 2017 May 11. Epub 2017 May 11.
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address:
    Background: TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity.

    Methods: The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up. Read More

    A rare coding allele in IFIH1 is protective for psoriatic arthritis.
    Ann Rheum Dis 2017 May 13. Epub 2017 May 13.
    Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK.
    Objectives: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. While many common risk alleles have been reported for association with PsA as well as psoriasis, few rare coding alleles have yet been identified.

    Methods: To identify rare coding variation associated with PsA risk or protection, we genotyped 41 267 variants with the exome chip and investigated association within an initial cohort of 1980 PsA cases and 5913 controls. Read More

    Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.
    Br J Dermatol 2017 May 12. Epub 2017 May 12.
    Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy.
    Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections. Read More

    Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients.
    Ther Clin Risk Manag 2017 2;13:583-592. Epub 2017 May 2.
    Department of Medical Research, Taichung Veterans General Hospital.
    Purpose: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA).

    Patients And Methods: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs. Multivariable analysis was used to estimate the effect of different therapies on the risk of DM. Read More

    Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    J Dermatol 2017 May 11. Epub 2017 May 11.
    Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
    Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range of comorbidities. The aim of this study was to evaluate the clinical significance of novel inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) in Japanese patients with plaque-type psoriasis (PsV) and psoriatic arthritis (PsA). One hundred and eighty-six patients with PsV and 50 patients with PsA treated with biologics, including infliximab, adalimumab and ustekinumab, were retrospectively analyzed before and after treatment. Read More

    Extracellular vesicles regulate the human osteoclastogenesis: divergent roles in discrete inflammatory arthropathies.
    Cell Mol Life Sci 2017 May 10. Epub 2017 May 10.
    Department of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad tér 4, 1089, Budapest, Hungary.
    Objective: Extracellular vesicles (EVs) are subcellular signalosomes. Although characteristic EV production is associated with numerous physiological and pathological conditions, the effect of blood-derived EVs on bone homeostasis is unknown. Herein we evaluated the role of circulating EVs on human osteoclastogenesis. Read More

    Tumor necrosis factor inhibitors in psoriatic arthritis.
    Expert Rev Clin Pharmacol 2017 May 22:1-12. Epub 2017 May 22.
    a Department of Pharmacology and Experimental Therapeutics , Thomas Jefferson University , Philadelphia , PA , USA.
    Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially. The clinical efficacy and the inhibition of radiographic progression demonstrated by TNFi have transformed the management of PsA. Read More

    New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions.
    Dermatology 2017 May 10. Epub 2017 May 10.
    Department of Rheumatology, Linyi People's Hospital, Shandong, China.
    Objectives: New interleukins (ILs), especially members of IL-1 and IL-12 families, have recently been reported to be involved in the development and regulation of autoimmune and inflammatory diseases. In this study, we aimed to explore the impact of these new ILs in psoriasis (Ps) and psoriatic arthritis (PsA).

    Methods: Forty PsA patients, 20 Ps patients, and 20 healthy controls (HCs) were recruited. Read More

    Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?
    Clin Rheumatol 2017 May 9. Epub 2017 May 9.
    Department of Internal Medicine, Pulmonology, Allergy and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine in Warsaw, Warsaw, Poland.
    A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Read More

    The role of IL-17 in the treatment of psoriatic arthritis.
    Expert Rev Clin Immunol 2017 May 16:1-7. Epub 2017 May 16.
    a Dipartimento di Medicina e Scienze della Salute "Vincenzo Tiberio" , Università degli Studi del Molise , Campobasso , Italy.
    Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory articular disease characterized by psoriasis, synovitis and enthesitis. Current treatment of PsA is mainly based on the use of classical and biological DMARDs; however, 30-40% of patients could not respond to these or have a loss of response. Areas covered: Recently, the discovery of new pathogenic mechanisms have made possible the development of new drugs that target the IL-17 with the possibility to interfere with the Th17 cells that are considered the cell type mainly involved in the development of the inflammation in PsA. Read More

    Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study.
    Ann Rheum Dis 2017 May 8. Epub 2017 May 8.
    Eli Lilly and Company, Indianapolis, Indiana, USA.
    Objectives: To examine the incidence and temporal trends of psoriatic arthritis (PsA) in the general population in Denmark.

    Methods: Using nationwide registry data, we estimated the number of patients with incident PsA within each 1-year period between 1997 and 2011 and calculated the rate of PsA cases within gender and age subgroups. Incidence rates were presented per 100 000 person-years. Read More

    Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.
    BMC Health Serv Res 2017 May 8;17(1):337. Epub 2017 May 8.
    Beijing Novartis Pharma Co. Ltd., Beijing, China.
    Background: Psoriasis is a multifactorial, inflammatory, skin disease associated with various comorbidities. The cost of those comorbidities is not well characterized. The present study assesses the incremental burden of comorbidities on healthcare resource utilization, direct costs and indirect costs associated with short-term disabilities among patients with psoriasis in the United States. Read More

    Isolation and Purification of Th9 Cells for the Study of Inflammatory Diseases in Research and Clinical Settings.
    Methods Mol Biol 2017 ;1585:247-255
    Florida Atlantic University, 777 Glades Road, Boca Raton, FL, USA.
    Th9 cells are associated with atopic and inflammatory diseases, and their increased levels and function correlate with the severity of symptoms in various inflammatory disorders including asthma, food allergy, atopic dermatitis, ulcerative colitis, and psoriatic arthritis. Thus, clinical trials are warranted to evaluate the role of Th9 cells in allergic diseases with the goal of controlling these ailments.Circulating T cells (naïve or memory CD4+ T cells) purified from human blood and expanded using anti-CD3 and anti-CD28 antibodies can be treated with appropriate cytokines in order to polarize them to the Th9 phenotype as evidenced by their production of IL-9. Read More

    Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
    Clin Rheumatol 2017 May 4. Epub 2017 May 4.
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
    The aim of the study is to examine the frequency and costs associated with above-label dosing of biologics in patients with psoriatic arthritis (PsA). MarketScan identified adults with ≥1 International Classification of Diseases, Clinical Modification diagnosis for PsA and ≥1 pharmacy claim for biologics of interest between January 1, 2011 and December 31, 2013. The first biologic claim was the index date with a 1-year follow-up period and three additional months to confirm continuous biologic use. Read More

    A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Ann Rheum Dis 2017 May 4. Epub 2017 May 4.
    The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
    Objectives: According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). We investigated disease activity before/after switching and retention rates in the DANBIO registry.

    Methods: Disease activities 3 months before and after switch and changes over time were calculated. Read More

    Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
    Ann Rheum Dis 2017 May 4. Epub 2017 May 4.
    University of Toronto and Toronto Western Hospital, Toronto, Canada.
    Objectives: To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA).

    Methods: This study randomised patients (1:1) with active PsA (~60% with prior exposure to a tumour necrosis factor inhibitor) to blinded weekly subcutaneous abatacept 125 mg (n=213) or placebo (n=211) for 24 weeks, followed by open-label subcutaneous abatacept. Patients without ≥20% improvement in joint counts at week 16 were switched to open-label abatacept. Read More

    [Fifteen years of the histopathological synovitis score : Review and further developments of a diagnostic score].
    Z Rheumatol 2017 May 3. Epub 2017 May 3.
    Klinikum Ernst von Bergmann gemeinnützige GmbH, Potsdam, Deutschland.
    The histopathological synovitis score evaluates in a graded approach, as is largely usual for diagnostic histopathological scores, the immunological and inflammatory changes caused by synovitis. A synovitis score of between 1 and ≤ 4 is classified as low-grade (osteoarthritis-related synovitis, post-traumatic synovitis, meniscopathy-related synovitis and synovitis in hemochromatosis). Synovitis scores of between ≥ 5 and 9 are classified as high-grade synovitis (rheumatoid arthritis, psoriatic arthritis, Lyme's arthritis, post-infection/reactive arthritis and peripheral arthritis in Bechterew disease); sensitivity is 61. Read More

    The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.
    Am Health Drug Benefits 2016 Dec;9(9):504-513
    Professor of Dermatology, Department of Dermatology, New York Medical College, Valhalla, NY.
    Background: Psoriasis is a debilitating chronic inflammatory autoimmune disease affecting approximately 7.4 million adults in the United States. Plaque psoriasis is the most common form, affecting 80% to 90% of patients. Read More

    Canadian Rheumatology Association Meeting, The Westin Ottawa, Ottawa, Ontario, Canada, February 8-11, 2017.
    J Rheumatol 2017 May 1. Epub 2017 May 1.
    The 72nd Annual Meeting of The Canadian Rheumatology Association (CRA) was held at The Westin Ottawa, Ottawa, Ontario, Canada, February 8-11, 2017. The program consisted of presentations covering original research, symposia, awards, and lectures. Highlights of the meeting include the following 2017 award winners: Dr. Read More

    1 OF 163